DENTSPLY SIRONA Inc. develops, manufactures and markets professional dental products, dental technologies, oral health products and other consumable medical devices under a broad brand portfolio. News for XRAY commonly covers quarterly results, outlook updates, restructuring actions, capital allocation, debt reduction, share repurchases and changes to distribution relationships for dental equipment and connected technology solutions.
Company updates also focus on digital dentistry and imaging products, including CEREC systems, intraoral scanning, CBCT imaging, DS Core, Smart View - Detect and dental-dedicated MRI work with Siemens Healthineers. Additional product news includes Surity urinary incontinence devices from Wellspect HealthCare, along with regulatory clearances, CE markings, commercial launches, board changes and investor conference participation.
Wellspect HealthCare (XRAY) announced the U.S. launch of the Surity™ Female External Catheter, a non-invasive product intended to help women with severe urinary incontinence and their caregivers. The device is designed to prevent leakage, protect skin, and support extended overnight use while integrating with compatible urine collection systems.
The company said Surity™ addresses a gap in continence care for aging, neurologic, and mobility-limited populations. The female catheter is available for home purchase at www.surity.care, and a Surity™ urinary management system plus a male external catheter are planned for launch later in the year.
Dentsply Sirona (Nasdaq: XRAY) and Patterson Dental announced on January 14, 2026 the renewal of their U.S. dental technology distribution agreement. The partnership continues long‑standing distribution of Dentsply Sirona’s technology portfolio—including CEREC, Primescan, Axeos and Orthophos—to Patterson Dental customers, supported by service and support. The companies say the renewal aims to accelerate adoption of integrated, connected dentistry solutions that link devices, software and services to improve practice efficiency and patient care.
The agreement emphasizes continued access to Dentsply Sirona products through Patterson Dental and a joint focus on growth and innovation in dental technology distribution in the U.S.
Dentsply Sirona (Nasdaq: XRAY) and Benco Dental announced an expanded partnership on Jan 13, 2026 where Benco will begin offering Dentsply Sirona’s full dental technology portfolio to US customers, in addition to consumables.
Available products include CEREC systems and blocks, intraoral scanners Primescan/Primescan 2, and extraoral imaging Axeos and Orthophos. Benco will open dedicated Dentsply Sirona experiences in three CenterPoint showrooms near Los Angeles, Dallas, and the NYC–Philadelphia area to support digital adoption and hands-on demos.
Dentsply Sirona (Nasdaq: XRAY) appointed Donald Zurbay to its Board of Directors, effective January 10, 2026. Mr. Zurbay will join the Board’s Audit and Finance Committee and brings leadership experience as former CEO and CFO of Patterson Companies and prior CFO of St. Jude Medical. The Board increased from 10 to 11 members.
The Board also formed a four-member Growth and Value Creation Committee, co-chaired by Gregory Lucier and Daniel Scavilla, to oversee the company’s Return-to-Growth action plan referenced on November 7, 2025.
Dentsply Sirona (Nasdaq: XRAY) appointed Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28, 2026. The hire is intended to strengthen commercial execution, deepen customer relationships and accelerate growth across the Americas. Bezjak joins from Zimmer Biomet, brings more than 20 years of commercial leadership and experience leading multi‑billion‑dollar organizations, and has a track record of commercial transformations and revenue and operating income growth. Management highlights his experience in orthopedics and customer‑first field execution as aligned with the company’s goal to elevate service to the dental community.
Dentsply Sirona (Nasdaq: XRAY) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 3:00 p.m. PT (6:00 p.m. ET).
Dan Scavilla, President and CEO, will discuss the company's Connected Dentistry portfolio, dental market trends, and progress on its return-to-growth strategy. A live audio webcast and replay will be available via the company's Investors website at https://investor.dentsplysirona.com.
DENTSPLY SIRONA (Nasdaq: XRAY) announced a quarterly cash dividend of $0.16 per share, equal to an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026 to shareholders of record as of December 26, 2025.
Dentsply Sirona (Nasdaq: XRAY) reported Q3 2025 results on November 6, 2025: net sales $904 million (down 5.0% reported, down 8.0% constant currency). GAAP net loss $427 million (loss per share $2.14); non-cash impairment charges were $263 million net of tax. On a non-GAAP basis, adjusted EPS $0.37, adjusted gross margin 52.6%, and adjusted EBITDA margin 18.4%. Operating cash flow was $79 million in Q3 and cash on hand was $363 million as of Sept 30, 2025.
The company launched a Return-to-Growth action plan, announced leadership changes including a CFO transition and a new Chief Transformation Officer, and revised FY25 guidance to $3.6B–$3.7B net sales and ~$1.60 adjusted EPS.
Dentsply Sirona (Nasdaq: XRAY) will host a third-quarter fiscal 2025 investor conference call and live webcast on Thursday, November 6, 2025 at 8:30 AM ET to review Q3 results. A press release and a presentation with summary financial information will be posted on the company's Investors website before the call. The live webcast and a replay will be available at https://investor.dentsplysirona.com. Registered participants may join the call via the provided registration link.
Dentsply Sirona (NASDAQ:XRAY), the world's largest diversified dental manufacturer, has appointed Aldo M. Denti as Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025.
Denti brings over 25 years of experience in Medical Device and Consumer Health sectors, most recently serving as Company Group Chairman, Global Orthopedics at Johnson & Johnson Medtech. The appointment aims to enhance customer focus by aligning Global Business Units and Commercial Organizations, streamlining operations and delivery processes.
CEO Daniel Scavilla highlighted that Denti will lead global sales strategy and execution to drive growth, profitability, and customer satisfaction across all regions. The new CCO role is designed to strengthen collaboration across business units and unlock synergies.